ASCO 2020 | IMvigor010: atezolizumab for UC

Thomas Powles, MBBS, MRCP, MD, Barts Cancer Institute, London, UK, provides an overview of IMvigor010 (NCT02450331), a Phase III, open-label, randomized, multicenter study is to evaluate the efficacy and safety of adjuvant treatment with atezolizumab compared with observation in participants with muscle-invasive urethelial carcinoma (UC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).